Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Merck and Idera form vaccine pact

December 18, 2006 | A version of this story appeared in Volume 84, Issue 51

Merck has licensed Idera Pharmaceuticals' toll-like receptor (TLR) agonists for use in vaccines it is developing for oncology, infectious diseases, and Alzheimer's disease. Merck will make an initial licensing payment of $20 million and has agreed to buy $10 million of Idera stock. Idera could receive up to $165 million in milestones if vaccines across all three therapeutic indications reach the market. Merck will combine its therapeutic and prophylactic vaccines with Idera compounds targeting TLRs 7, 8, and 9, which help mediate human immune response.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.